ArticleCureus2025
Validity of the New International Diabetes Federation-Diabetes and Ramadan (IDF-DAR) Risk Stratification Score and Fasting Experience of Saudi Patients With Diabetes During Ramadan: Insights From a Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Factors associated with hypoglycemic or hyperglycemic events during Ramadan among persons with diabetes in Qatar.BMJ open diabetes research & care · 2026Article
- Fasting safely during Ramadan with diabetes: clinical practice recommendations for Arab populations from the Arab Diabetes Forum (FSR-ADF).Hormones (Athens, Greece) · 2026Review
- The proportion of diabetic ketoacidosis emergencies during Ramadan fasting: a retrospective study.Frontiers in endocrinology · 2026Observational
- Evolution of the risk concept and assessment tools for diabetes during Ramadan fasting: A narrative review.World journal of diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The International Diabetes Federation-Diabetes and Ramadan (IDF-DAR) risk stratification tool is designed to predict adverse outcomes in patients with diabetes who fast during Ramadan. Objectives This study evaluates the accuracy of the IDF-DAR tool in predicting adverse outcomes among Saudi patients with diabetes intending to fast during Ramadan while comparing outcomes across different risk categories. Methods This prospective observational study was conducted at the Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, and diabetes clinics at King Abdulaziz Medical City in Riyadh, Saudi Arabia. Data were collected through questionnaires on diabetes characteristics, complications, comorbidities, and factors influencing fasting. Ordinal regression analysis was performed to identify predictors of risk levels. Results The cohort consisted of 303 patients, including 163 females (53.5%) with a mean age of 50.49 ± 17.91 years. Type 2 diabetes mellitus was diagnosed in 217 participants (71.6%), and 231 patients (76.2%) had diabetes for over 10 years. Risk stratification categorized 39 patients (12.9%) as low risk, 71 (23.4%) as moderate risk, and 193 (63.7%) as high risk. Self-monitoring of blood glucose adherence was reported in 174 patients (57.4%), with the highest adherence in the high-risk group (126 or 65.3%) and the lowest in the low-risk group (18 or 46.2%). Hyperglycemia (>16.6 mmol/L) was observed in 141 participants (47%): 13 (33.3%) low risk, 26 (36.6%) moderate risk, and 103 (53.4%) high risk. Hypoglycemia was the most common reason for breaking the fast, notably among 23 patients (71.9%) fasting for more than 15 days. A significant majority of participants aimed to fast for the full 30 days, with the highest completion rate among moderate-risk individuals at 58 (81.7%). In contrast, 27 individuals (14.92%) in the high-risk group did not fast at all. Conclusions The IDF-DAR tool effectively stratifies fasting risk in diabetic patients but may not accurately reflect the risk for some high-risk individuals. Further validation is necessary to enhance its predictive accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.